| $350M | ||
| $217M | ||
| $172M | ||
| $109M | ||
| $107M | ||
| $104M |
Buys | $61,078 | 2 | 100 |
Sells | $0 | 0 | 0 |
| Shen Ethan PhD | CEO | 2 | $61,078 | 0 | $0 | $61,078 |
YD Bio Limited, a biopharmaceutical company, focuses on regulated diagnostics, life science clinical services, and healthcare product commercialization in the United States and Taiwan. The company offers eye disease treatment products, 3D LensMate Artificial Tears, a natural tear-mimicking lubricant that moisturizes the eyes and relieves dry eye symptoms; 3D LensMate Eye Drops, an ophthalmic solution to alleviate symptoms of dry eye syndrome, including irritation, foreign body sensation, and eye fatigue; and LSC Eye Drug/Injection, an …
Over the last 12 months, insiders at YD Bio Limited Ordinary Shares have bought $61,078 and sold $0 worth of YD Bio Limited Ordinary Shares stock.
On average, over the past 5 years, insiders at YD Bio Limited Ordinary Shares have bought $61,078 and sold $0 worth of stock each year.
Highest buying activity among insiders over the last 12 months: Shen Ethan PhD (CEO) — $61,078.
The last purchase of 12,700 shares for transaction amount of $48,895 was made by Shen Ethan PhD (CEO) on 2026‑09‑14.
| 2026-09-14 | Shen Ethan PhD | CEO | 12,700 0.0191% | $3.85 | $48,895 | +54.83% | ||
| 2026-09-09 | Shen Ethan PhD | CEO | 3,100 0.0044% | $3.93 | $12,183 | +49.62% |
| Increased Positions | 5 | +31.25% | 21,071 | +12.01% |
| Decreased Positions | 7 | -43.75% | 54,999 | -31.34% |
| New Positions | 4 | New | 15,779 | New |
| Sold Out Positions | 4 | Sold Out | 39,467 | Sold Out |
| Total Postitions | 14 | -12.5% | 141,580 | -19.33% |